-

Lost Money in Harmony Biosciences Holdings Inc.?

Gibbs Law Group Investigates Potential Securities Law Violations

OAKLAND, Calif.--(BUSINESS WIRE)--Shares of Harmony Biosciences plummeted 27% on Tuesday, March 28, 2023, after Scorpion Capital published a report alleging that serious health risks, including sudden death, occurred during foreign drug trials of Harmony Bioscience’s drug, Wakix. The report further alleges that the company concealed information from the FDA that would have prevented Wakix’s 2019 approval. Gibbs Law Group is looking into a potential Harmony Biosciences Class Action Lawsuit on behalf of investors who lost money in Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY).

To speak with an attorney regarding this class action lawsuit investigation, click here or call (888) 410-2925.

On Tuesday, March 28, 2023, Scorpion Capital released an investigative report claiming that pharmaceutical company Harmony Biosciences’ narcolepsy drug, Wakix, is a repeat of another similar drug that the FDA previously pulled from the market due to cardiac toxicity. The report details “12 sudden deaths in the foreign clinical trials, all in the drug arm, none in placebo" and alleges that the company provided “sham safety studies” that misled the FDA into approving the drug back in 2019. Scorpion Capital adds that it obtained “dozens of serious adverse event reports” from the FDA that “paint a devastating picture of the drug’s risk to even young, otherwise healthy patients,” and it is now planning to file a Citizen’s Petition with the FDA to request withdrawal of Wakix’s approval.

Following this news, Harmony Biosciences’ stock price dropped 27%, causing significant losses for investors.

What Should Harmony Biosciences Investors Do?

If you invested in Harmony Biosciences, visit our website or contact our securities team directly at (888) 410-2925 to discuss how you may be able to recover your losses. Our investigation concerns whether Harmony Biosciences has violated federal securities laws.

About Gibbs Law Group

Gibbs Law Group represents individual and institutional investors throughout the country in securities litigation to correct abusive corporate governance practices, breaches of fiduciary duty, and proxy violations. The firm has recovered over a billion dollars for its clients against some of the world’s largest corporations, and our attorneys have received numerous honors for their work, including “Best Lawyers in America,” “Top Plaintiff Lawyers in California,” “California Lawyer Attorney of the Year,” “Top Class Action Attorneys Under 40,” “Consumer Protection MVP,” and “Top Cybersecurity/ Privacy Attorneys Under 40.”

This press release may constitute Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

EILEEN EPSTEIN CARNEY
PHONE: 510.350.9728
EMAIL: EJE@CLASSLAWGROUP.COM

Gibbs Law Group

NASDAQ:HRMY

Release Summary
Gibbs Law Group is investigating potential claims on behalf of Harmony Biosciences (HRMY) investors.
Release Versions
$Cashtags
Hashtags

Contacts

EILEEN EPSTEIN CARNEY
PHONE: 510.350.9728
EMAIL: EJE@CLASSLAWGROUP.COM

More News From Gibbs Law Group

Top Plaintiff Firms Join Forces for Law Students: The Mason Gibbs Plaintiffs' Pathway Fellowship

OAKLAND, Calif.--(BUSINESS WIRE)--The Mason Gibbs Plaintiffs’ Pathway Fellowship has now launched, offering exceptional 1L law students the opportunity to spend their summer at leading plaintiff firms across the country holding corporations accountable for misconduct and protecting the rights of ordinary individuals. Students will have the opportunity to be placed in the summer of 2026 at Gibbs Mura LLP, in Oakland, CA; Singleton Schreiber, with 17 offices in different cities; Koskoff Koskoff &...

Ardent Health, Inc. (ARDT) Under Investigation After Shares Plummet Over 33%

OAKLAND, Calif.--(BUSINESS WIRE)--Gibbs Mura is investigating a potential securities class action lawsuit on behalf of Ardent Health, Inc. (NYSE: ARDT) investors....

Lawsuit Filed Against Stride, Inc. (LRN) After Shares Plummet Over 51%

OAKLAND, Calif.--(BUSINESS WIRE)--Gibbs Mura announces that a class action lawsuit has been filed against Stride, Inc. (“Stride”) on behalf of investors who purchased or acquired Stride securities between October 22, 2024 and October 28, 2025. Shares of Stride, Inc. plummeted over 51% in intraday trading on October 29, 2025, after the company reported a weak 2026 financial forecast, citing platform upgrades that resulted in a “poor customer experience” and a large decrease in enrollment numbers...
Back to Newsroom